Background: Acute myeloid leukemia (AML) is a common hematological malignancy characterized by the clonal growth of myeloblasts/promyelocytes not only in the bone marrow but also in peripheral blood and/or tissues. Thrombosis is a major complication; early detection of thrombotic event is the important of its treatment. Von Willebrand factor (VWF) is a major component of hemostasis. Soluble fibrin monomer complex (SFMC) forms in early stage of thrombus formation by fusion of two fibrinogen molecules and one fibrin monomer. Objective: To assess the levels of VWF Ag, a disintegrin and metalloproteinase with a thrombospondin type I motif, member13 (ADAMTS13), D dimer & SFMC in patients with AML. Patients and methods: The study was conducted on 40 patients newly diagnosed as AML patients. They were compared with 40 healthy individuals with identical demographic characteristics not suffering from any disease. Levels of VWF Ag, ADAMTS13, D dimer and SFMC were measured in both groups by enzyme linked immunosorbent assay (ELISA).This study carried out over a period from April2019 and March 2020, at Sayed Galal University Hospital. Results: A significant increase in VWF Ag, SFMC, DD and a significant decrease in ADAMTS13 level occurred in all patients with AML compared with control group. (p=<0.0001). Conclusion: VWF and ADAMTS13 played an important role in hypercoagulability state in AML patients. SFMC could be used as an early indicator of hypercoagulability.